Bristol-Myers Squibb Company (NYSE: BMY) announced today that treatment with Opdivo (nivolumab) 3 mg/kg resulted in a significant improvement in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 TrialSeptember 11, 2017 6:16 AM Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 StudySeptember 10, 2017 6:11 PM Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung CancerSeptember 8, 2017 5:49 AM Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Goldman Sachs, Positively Revises EPS EstimatesSeptember 7, 2017 9:53 AM Wall St. ends flat as media stocks slump, healthcare gainsSeptember 7, 2017 7:39 AM Bristol-Myers Squibb (BMY) Reports CheckMate-214 Study Evaluating Opdivo in Combination with Yervoy Meets Co-Primary Endpoint, Demonstrating Superior Overall Survival Compared to SunitinibSeptember 7, 2017 7:02 AM